Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy

Overview

Journal Clin Gastroenterol Hepatol

Specialty Gastroenterology

Date 2015 May 24

PMID 26001336

Citations 10

Authors

Emanuelle Bellaguarda

Kian Keyashian

Joel Pekow

David T Rubin

Russell D Cohen

Atsushi Sakuraba

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Natalizumab, a humanized antibody against the α4 integrin subunit, effectively induces and maintains remission in patients with Crohn's disease (CD) refractory to conventional treatments. Progressive multifocal leukoencephalopathy is a rare but fatal brain infection caused by John Cunningham (JC) virus and has been associated with natalizumab use. We assessed the prevalence of and risk factors for antibodies to JC virus in serum of patients with refractory CD who were candidates for, or already were receiving, natalizumab. We also assessed the effects of natalizumab treatment of these patients.

Methods: In a retrospective study, we analyzed clinical charts from 191 patients with CD (74 males; mean age, 38.7 y; mean duration of disease, 14.9 y) tested for serum JC virus antibody from December 2012 through May 2014 at 2 medical centers in the United States. We calculated JC virus antibody prevalence and compared the characteristics of patients who tested negative vs those who tested positive, to identify risk factors. We also assessed the rate of subsequent natalizumab use, surgery, and seroconversion during natalizumab therapy.

Results: A total of 129 of the patients (67.5%) tested positive for serum JC virus antibody. Multivariate analysis showed that past use of thiopurine was a risk factor for testing positive for JC virus antibody (odds ratio, 7.8; 95% confidence interval, 2.0-30.4; P = .003). Twenty-two of the patients who tested negative for JC virus antibody (35.5%) and 16 of the 129 patients who tested positive (12.4%) had been treated with natalizumab. Cox regression analysis determined that natalizumab use was the only factor associated with avoiding subsequent surgery (hazard ratio, 0.23; 95% confidence interval, 0.06-0.98). Seroconversion (from testing negative to positive for JC virus antibody) occurred in 1 of the 22 patients (4.5%) who initially tested negative during natalizumab therapy.

Conclusions: The prevalence of CD patients exposed to JC virus is comparable with that of the general population. In this retrospective study, prior thiopurine use was associated with an increased risk for testing positive for JC virus antibody. Natalizumab use reduced the risk of subsequent surgery.

Citing Articles

Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.

Rindi L, Zace D, Braccialarghe N, Massa B, Barchi V, Iannazzo R Drug Saf. 2024; 47(4):333-354.

PMID: 38321317 DOI: 10.1007/s40264-023-01383-4.

Pathological mechanism and targeted drugs of ulcerative colitis: A review.

Guo M, Wang X Medicine (Baltimore). 2023; 102(37):e35020.

PMID: 37713856 PMC: 10508406. DOI: 10.1097/MD.0000000000035020.

Comparison of the gut virus communities between patients with Crohn's disease and healthy individuals.

Ding Y, Wan M, Li Z, Ma X, Zhang W, Xu M Front Microbiol. 2023; 14:1190172.

PMID: 37396350 PMC: 10311494. DOI: 10.3389/fmicb.2023.1190172.

Involvement of HHV-4 (Epstein-Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis.

Marongiu L, Venturelli S, Allgayer H Cancers (Basel). 2022; 14(20).

PMID: 36291869 PMC: 9599759. DOI: 10.3390/cancers14205085.

The Role of the Lymphatic System in the Pathogenesis and Treatment of Inflammatory Bowel Disease.

Nikolakis D, de Voogd F, Pruijt M, Grootjans J, van de Sande M, DHaens G Int J Mol Sci. 2022; 23(3).

PMID: 35163775 PMC: 8836364. DOI: 10.3390/ijms23031854.

References

Gu Z, Li Q, Si Y, Li X, Hao H, Song H . Prevalence of BK virus and JC virus in peripheral blood leukocytes and normal arterial walls in healthy individuals in China. J Med Virol. 2003; 70(4):600-5. DOI: 10.1002/jmv.10436. View

Bhan V, Lapierre Y, Freedman M, Duquette P, Selchen D, Migounov V . Anti-JC Virus Antibody Prevalence in Canadian MS Patients. Can J Neurol Sci. 2014; 41(6):748-52. DOI: 10.1017/cjn.2014.32. View

Rutgeerts P, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126(2):402-13. DOI: 10.1053/j.gastro.2003.11.014. View

Taguchi F, Kajioka J, Miyamura T . Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol. 1982; 26(11):1057-64. DOI: 10.1111/j.1348-0421.1982.tb00254.x. View

Langer-Gould A, Atlas S, Green A, Bollen A, Pelletier D . Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005; 353(4):375-81. DOI: 10.1056/NEJMoa051847. View

Sandborn W, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I . Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353(18):1912-25. DOI: 10.1056/NEJMoa043335. View

Hanauer S . Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2005; 12 Suppl 1:S3-9. DOI: 10.1097/01.mib.0000195385.19268.68. View

Tyler K, Khalili K . Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA. Rev Neurol Dis. 2006; 2(3):144-9. View

Hanauer S, Sandborn W, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130(2):323-33. DOI: 10.1053/j.gastro.2005.11.030. View

10.

Hibi T, Ogata H . Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol. 2006; 41(1):10-6. DOI: 10.1007/s00535-005-1744-3. View

11.

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

12.

Xavier R, Podolsky D . Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448(7152):427-34. DOI: 10.1038/nature06005. View

13.

Verbeeck J, Van Assche G, Ryding J, Wollants E, Rans K, Vermeire S . JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?. Gut. 2008; 57(10):1393-7. DOI: 10.1136/gut.2007.145698. View

14.

Linda H, von Heijne A, Major E, Ryschkewitsch C, Berg J, Olsson T . Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009; 361(11):1081-7. DOI: 10.1056/NEJMoa0810316. View

15.

Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T . Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology. 2009; 137(5):1736-45. DOI: 10.1053/j.gastro.2009.07.049. View

16.

Clifford D, De Luca A, DeLuca A, Simpson D, Arendt G, Giovannoni G . Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010; 9(4):438-46. DOI: 10.1016/S1474-4422(10)70028-4. View

17.

Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K . Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010; 68(3):295-303. DOI: 10.1002/ana.22128. View

18.

Brew B, Davies N, Cinque P, Clifford D, Nath A . Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010; 6(12):667-79. DOI: 10.1038/nrneurol.2010.164. View

19.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A . Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012; 366(20):1870-80. DOI: 10.1056/NEJMoa1107829. View

20.

Sakuraba A, Sato T, Matsukawa H, Okamoto S, Takaishi H, Ogata H . The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study. Int J Colorectal Dis. 2012; 27(7):947-52. DOI: 10.1007/s00384-011-1398-y. View